Get startedLog in
    Picture of Finch Therapeutics logo

    FNCHQ — Finch Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro Cap
    All News

    Brief: Finch Therapeutics Reports Q3 2022 Financial Results

    Picture of Finch Therapeutics logoFinch Therapeutics
    10/11/2022 12:45
    Nov 10 (Reuters) - Finch Therapeutics Group Inc
 FNCH.O :
    * FINCH THERAPEUTICS PROVIDES CORPORATE UPDATES AND REPORTS
THIRD
QUARTER 2022 FINANCIAL RESULTS
    * FINCH THERAPEUTICS GROUP INC - PATIENT DOSING UNDERWAY IN
PRISM4
PHASE 3 TRIAL OF CP101 IN RECURRENT CDI
    * FINCH THERAPEUTICS GROUP INC - TOPLINE PRISM4 DATA
ANTICIPATED
IN H1 2024
    * FINCH THERAPEUTICS GROUP INC - ANTICIPATED CASH RUNWAY
INTO Q2
2024
    * FINCH THERAPEUTICS GROUP INC - CASH AND CASH EQUIVALENTS
AS OF
SEPTEMBER 30, 2022 WERE $85.3 MILLION, COMPARED TO $133.5
MILLION AS OF DECEMBER 31, 2021
    * FINCH THERAPEUTICS GROUP INC - QTRLY LOSS PER SHARE $0.85

Source text for Eikon:  ID:nGNX96fnvM 
Further company coverage:  FNCH.O 
 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Finch Therapeutics

    See all news